Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 35Glioblastoma 24Carcinoma, Non-Small-Cell Lung 21Ovarian Neoplasms 14Carcinoma, Hepatocellular 14Brain Neoplasms 14Carcinoma, Renal Cell 13Pancreatic Neoplasms 12Neoplasms 10Neoplasm Metastasis 10Glioma 10Breast Neoplasms 10Colonic Neoplasms 8Astrocytoma 8Melanoma 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Liver Neoplasms 6Gliosarcoma 6Endometrial Neoplasms 6Stomach Neoplasms 5Lung Neoplasms 5Fallopian Tube Neoplasms 5Colorectal Cancer Metastatic 5Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Oligodendroglioma 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3

Interventions

talimogene laherparepvec 1rilotumumab 1ganitumab 1camrelizumab 1Thiostrepton 1Silver Nitrate 1Nivolumab 1Etoposide 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pleural Effusion, Malignant × Bevacizumab × Clear all
NCT05330065 2022-04-15

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

The First Affiliated Hospital of Zhengzhou University

Phase 1/2 Unknown
55 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡